| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8964511 | Clinical Oncology | 2018 | 8 Pages |
Abstract
Our series shows comparable survival rates with published data despite an unselected population. The transition to neoadjuvant chemotherapy before CRT has improved tolerability and increased rates of completion of treatment. The locoregional failure rate remains significant and strategies for improving this, such as changing the chemotherapy back bone and radiation dose escalation, are eagerly awaited within the SCOPE-2 study.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
V.J. Lavin, S. Mehta, P. Sumra, X. Wang, L. Bhatt, A.S. Jackson, H.Y. Sheikh,